ISSN : 2146-3123
E-ISSN : 2146-3131

Frequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)
Elif Tanrıverdi1, Nuri Tutar2, Ayşegül Şentürk3, Ayşe Bahadır4, Nimet Aksel5, Nur Aleyna Yetkin2, Gülistan Karadeniz5, Nazlı Çetin6, Ali Tabaru7, Binnaz Zeynep Yıldırım1, Hatice Selimoğlu Şen8, Neslihan Özçelik9, Emine Özsarı10, Fatih Uzer11, Tuğba Çiçek12, Dorina Esendağlı13, İclal Hocanlı14, Nagihan Durmuş Koçak15, Utku Tapan16, Bahar Kurt17, Sibel Arınç18, Murat Kavas18, Füsun Şahin1, Dilek Ergun19, Elif Yılmazel Uçar20, Talat Kılıç21, İnci Gülmez22, Jülide Celdir Emre23, Deniz Doğan24, Fatma Özdemir25, Mustafa Düger26, Suha Alzafer27, Esra Yarar28, Damla Serce Unat5, Bilge Salık5
1Clinic of Chest Diseases, University of Health Sciences Turkey, Yedikule Pulmonary Diseases and Thoracic Surgery Education and Research Hospital, İstanbul, Turkey
2Department of Pulmonary, Faculty of Medicine, Erciyes University, Kayseri, Turkey
3Clinic of Pulmonary Diseases, University of Health Sciences Turkey, Atatürk Pulmonary Diseases and Thoracic Surgery Education and Research Hospital, Erzurum, Turkey
4Clinic of Chest Diseases, Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey
5Clinic of Chest Diseases, University of Health Sciences Turkey, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Turkey
6Deparment of Pulmonology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
7Clinic of Pulmonology, Söke City Hospital, Aydın, Turkey
8Department of Chest Disease, Faculty of Medicine, Dicle University, Diyarbakır, Turkey
9Department of Pulmonology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey
10Department of Pulmonology, Faculty of Medicine, Abant İzzet Baysal University, Bolu, Turkey
11Clinic of Respiratory Disease, Kastamonu State Hospital, Kastamonu, Turkey
12Clinic of Chest Disease, Konya Numune Hospital, Konya, Turkey
13Department of Pulmonology, Faculty of Medicine, Başkent University, Ankara, Turkey
14Department of Pulmonology, Faculty of Medicine, Harran University, Şanlıurfa, Turkey
15Clinic of Chest Disease, Sancaktepe Şehit Prof. Dr. İlhan Varank Research and Training Hospital, İstanbul, Turkey
16Department of Chest Diseases, Faculty of Medicine, Muğla Sıtkı Koçman University, Muğla, Turkey
17Clinic of Chest Disease, Dışkapı Education and Research Hospital, Ankara, Turkey
18Clinic of Chest Diseases, University of Health Sciences Turkey, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey
19Department of Chest Disease, Faculty of Medicine, Selçuk University, Konya, Turkey
20Department of Chest Disease, Faculty of Medicine, Atatürk University, Erzurum, Turkey
21Department of Chest Disease, Faculty of Medicine, İnönü University, Malatya, Turkey
22Department of Chest Disease, Faculty of Medicine, Erciyes University, Kayseri, Turkey
23Clinic of Pulmonology, Turgutlu State Hospital, Manisa, Turkey
24University of Health Sciences Turkey, Gülhane Training and Research Hospital, Ankara, Turkey
DOI : 10.4274/balkanmedj.galenos.2021.2021-10-19
Pages : 148-152

Abstract

Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary.
Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results.
Study Design: Cross-sectional study
Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially.
Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients.
Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.

Viewed : 648
Downloaded : 246